<DOC>
	<DOC>NCT02728193</DOC>
	<brief_summary>The aim of our study was to elucidate the difference in the rates of complication, hospitalization days, medical expenses, MRI showed that the degree of tumor necrosis, and overall survival rates of the therapies between PEI, MVA and RFA, and make the standard for minimally invasive treatment of very early stage HCC.</brief_summary>
	<brief_title>Standard Treatments of Very-early Stage Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>1. Preoperative clinical, imaging and tumor markers were diagnosed as hepatocellular carcinoma 2. Tumor diameter&lt;2cm 3. ChildPugh class A liver function 4. Without major organ dysfunction 5. male or female patients &gt; 18 years and &lt;=70 years of age 6. Voluntary participation in this clinical trial 1. Other anticancer treatment before therapy 2. Patients with apparent major organs (i.e. cardiac, pulmonary, cerebral and renal) dysfunction, which may affect the treatment of liver cancer 3. Patients with other diseases that may affect the treatment of this treatment 4. History of other malignant tumors 5. Patients who are participating in other clinical trials 6. Pregnant, lactating women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>treatments</keyword>
	<keyword>hepatocellular carcinoma</keyword>
</DOC>